Vivos Therapeutics Inc. (NASDAQ:VVOS) shares traded 154.05% higher at $1.88 on Wall Street last session.
In accordance with the data, 1 analysts cover Vivos Therapeutics Inc. (NASDAQ:VVOS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $2.00, we find $2.00. Given the previous closing price of $0.74, this indicates a potential upside of 170.27 percent. VVOS stock price is now 236.09% away from the 50-day moving average and 53.65% away from the 200-day moving average. The market capitalization of the company currently stands at $42.09M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $2.00 as their price target over the next twelve months.
.
In other news, Huntsman Ronald Kirk, Chief Executive Officer bought 20,000 shares of the company’s stock on Dec 23. The stock was bought for $10,000 at an average price of $0.50. Upon completion of the transaction, the Chief Executive Officer now directly owns 47,500 shares in the company, valued at $89300.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 01, Chief Executive Officer Huntsman Ronald Kirk bought 4,000 shares of the business’s stock. A total of $7,320 was incurred on buying the stock at an average price of $1.83. This leaves the insider owning 27,500 shares of the company worth $51700.0. A total of 21.68% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VVOS stock. A new stake in Vivos Therapeutics Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $98,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $78,000 in shares of VVOS during the first quarter. In the first quarter, APEXIUM FINANCIAL, LP acquired a new stake in Vivos Therapeutics Inc. valued at approximately $76,000. SEACREST WEALTH MANAGEMENT, LLC acquired a new stake in VVOS for approximately $75,000. WEALTH ALLIANCE ADVISORY GROUP, LLC purchased a new stake in VVOS valued at around $66,000 in the second quarter. In total, there are 35 active investors with 8.90% ownership of the company’s stock.
Vivos Therapeutics Inc. (NASDAQ: VVOS) opened at $2.0600 on Wednesday. During the past 12 months, Vivos Therapeutics Inc. has had a low of $0.34 and a high of $3.69. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.60, and a quick ratio of 1.60. The fifty day moving average price for VVOS is $0.5594 and a two-hundred day moving average price translates $1.2235 for the stock.
The latest earnings results from Vivos Therapeutics Inc. (NASDAQ: VVOS) was released for Mar, 2022. According to the Medical Devices Company, earnings per share came in at -$0.26, inline with analysts’ expectations of -$0.26. This compares to -$0.26 EPS in the same period last year. The company reported revenue of $4.25 million for the quarter, compared to $4.55 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.6 percent. For the current quarter, analysts expect VVOS to generate $3.81M in revenue.
Vivos Therapeutics Inc.(VVOS) Company Profile
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
